Ascendis Pharma (Nasdaq:ASND) - Cotización, noticias y análisis

Resumen de acción ASND

Ascendis Pharma A/S, empresa biofarmacéutica, se centra en el desarrollo de terapias para necesidades médicas no cubiertas. Saber más

Análisis fundamental de ASND
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	5/6
Rendimiento pasado	0/6
Salud financiera	1/6
Dividendos	0/6

Recompensas

Cotiza un 80.3% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 71.42%

Análisis de riesgos

Patrimonio neto negativo

Los accionistas han sido diluidos en el último año

Competidores de Ascendis Pharma A/S

Arcellx

NasdaqGS:ACLX

US$4.7b

TG Therapeutics

NasdaqCM:TGTX

US$4.2b

Legend Biotech

NasdaqGS:LEGN

US$7.0b

Global Blood Therapeutics

NasdaqGS:GBT

US$4.6b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Ascendis Pharma
Precios históricos de las acciones
Precio actual de la acción	US$126.51
Máximo en las últimas 52 semanas	US$161.00
Mínimo de 52 semanas	US$90.13
Beta	0.65
1Cambio en 1 mes	-2.61%
Variación en 3 meses	-8.21%
Cambio de 1 año	33.18%
3Variación en 3 años	-14.99%
Variación en 5 años	11.68%
Variación desde la OPV	571.85%

Noticias y actualizaciones recientes

Recent updates

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Oct 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Jun 27

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

May 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Feb 18

Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Sep 24

Ascendis Pharma: TransCon CNP Data Coming Q4

Sep 15

Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH

Aug 31

Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa

Aug 11

Rentabilidad de los accionistas

	ASND	US Biotechs	Mercado US
7D	1.8%	-10.3%	-2.1%
1Y	33.2%	13.6%	29.6%

Rentabilidad vs. Industria: ASND superó a la industria US Biotechs, que obtuvo un rendimiento del 13.6% el año pasado.

Rentabilidad vs. Mercado: ASND superó al mercado US, que obtuvo un rendimiento del 29.6% el año pasado.

Volatilidad de los precios

Is ASND's price volatile compared to industry and market?
ASND volatility
ASND Average Weekly Movement	7.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Precio estable de las acciones: ASND no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ASND (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2006	879	Jan Mikkelsen	ascendispharma.com

Ascendis Pharma A/S, empresa biofarmacéutica, se centra en el desarrollo de terapias para necesidades médicas no cubiertas. Ofrece SKYTROFA para el tratamiento de pacientes con deficiencia de la hormona del crecimiento (GHD). La empresa también está desarrollando una cartera de tres productos candidatos independientes para enfermedades raras endocrinológicas en fase de desarrollo clínico, además de centrarse en el avance de candidatos terapéuticos oncológicos.

Resumen de fundamentos de Ascendis Pharma A/S

¿Cómo se comparan los beneficios e ingresos de Ascendis Pharma con su capitalización de mercado?
Estadísticas fundamentales de ASND
Capitalización bursátil	US$7.56b
Beneficios(TTM)	-US$448.99m
Ingresos (TTM)	US$344.70m

21.9x

Ratio precio-ventas (PS)

-16.8x

Ratio precio-beneficio (PE)

¿Está ASND sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ASND
Ingresos	€327.43m
Coste de los ingresos	€49.69m
Beneficio bruto	€277.74m
Otros gastos	€704.23m
Beneficios	-€426.49m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-7.14
Margen bruto	84.82%
Margen de beneficio neto	-130.26%
Ratio deuda/patrimonio	-810.4%

¿Cómo se ha desempeñado ASND a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ASND

Recompensas

Análisis de riesgos

Competidores de Ascendis Pharma A/S

NasdaqGS:ACLX

US$4.7b

NasdaqCM:TGTX

US$4.2b

NasdaqGS:LEGN

US$7.0b

NasdaqGS:GBT

US$4.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Ascendis Pharma A/S to Report Q3, 2024 Results on Nov 14, 2024

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Ascendis Pharma A/S to Report Q3, 2024 Results on Nov 14, 2024

Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million.

Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024

Consensus revenue estimates fall by 19%

Ascendis Pharma Takes A Big Price Cut On Skytrofa

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024

Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults

Ascendis Pharma A/S' (NASDAQ:ASND) Share Price Could Signal Some Risk

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Consensus EPS estimates fall by 13%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

Consensus estimates of losses per share improve by 17%

President notifies of intention to sell stock

President notifies of intention to sell stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Consensus revenue estimates increase by 12%

Ascendis Pharma's Ambitious Vision 2030

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

President notifies of intention to sell stock

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

New major risk - Negative shareholders equity

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Consensus revenue estimates decrease by 11%

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Key Executive notifies of intention to sell stock

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Consensus revenue estimates increase by 24%

Independent Chairman notifies of intention to sell stock

New major risk - Financial position

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023